News

IMPENTRI IMI2Follow

International COVID-19 trial to restart with focus on immune responses https://www.nature.com/articles/d41586-021-01090-z

Reply on Twitter 1391712907021406210 Retweet on Twitter 1391712907021406210 Like on Twitter 13917129070214062102 Twitter 1391712907021406210

3 Feb

Excited to announce that the clinical trial of Impentri in patients with #COVID19 associated ARDS has been approved. Hope to recruit the first patient soon.

Reply on Twitter 1357019438252515328 Retweet on Twitter 1357019438252515328 Like on Twitter 13570194382525153283 Twitter 1357019438252515328

14 Dec

Two highly relevant, recent @Nature papers have been published to deepen our understanding of the potential benefit of imatinib for the treatment of #Covid_19:
https://doi.org/10.1038/s41586-020-2901-9
and https://doi.org/10.1038/s41586-020-03065-y

Reply on Twitter 1338417061589086208 Retweet on Twitter 1338417061589086208 Like on Twitter 1338417061589086208 Twitter 1338417061589086208

CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19

Results published on Friday 18 June in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 [...]

Could this cancer drug fight fluid build-up in the lungs of COVID patients?

IMPENTRI will look for clinical proof of the benefit of imatinib in Covid-19 acute respiratory distress syndrome The build-up of fluid in the lungs is common among [...]

IMI2 Grant awarded to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS

CAMBRIDGE, UK AND DUBLIN, IRELAND, May 13 2020 / / — Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, today announced the [...]